NEUROCRINE BIOSCIENCES INC Cost of Goods Sold (Deprecated 2018-01-31)
NEUROCRINE BIOSCIENCES INC (NBIX) reported Cost of Goods Sold (Deprecated 2018-01-31) of $950.00 thousand for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-04-30.
Discontinued › Expense Statement
us-gaap:CostOfGoodsSold · last filed 2018-04-30
- NEUROCRINE BIOSCIENCES INC cost of goods sold (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $950.00K.
- NEUROCRINE BIOSCIENCES INC cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $760.00K.
- NEUROCRINE BIOSCIENCES INC cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $433.00K.
- NEUROCRINE BIOSCIENCES INC cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $61.00K.
- NEUROCRINE BIOSCIENCES INC cost of goods sold (deprecated 2018-01-31) for fiscal 2017 was $1.25M.
- NEUROCRINE BIOSCIENCES INC cost of goods sold (deprecated 2018-01-31) for fiscal 2016 was $0.00.
- NEUROCRINE BIOSCIENCES INC cost of goods sold (deprecated 2018-01-31) for fiscal 2015 was $0.00.
| Period end | Cost of Goods Sold (Deprecated 2018-01-31) 3 month | Cost of Goods Sold (Deprecated 2018-01-31) 6 month | Cost of Goods Sold (Deprecated 2018-01-31) 9 month | Cost of Goods Sold (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $950.00K 10-Q · filed 2018-04-30 | $1.71M derived: sum of 2 quarters · filed 2018-04-30 | $2.14M derived: sum of 3 quarters · filed 2018-04-30 | $2.20M derived: sum of 4 quarters · filed 2018-04-30 |
| 2017-12-31 | $760.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $1.19M derived: sum of 2 quarters · filed 2018-02-13 | $1.25M derived: sum of 3 quarters · filed 2018-02-13 | $1.25M 10-K · filed 2018-02-13 |
| 2017-09-30 | $433.00K 10-Q · filed 2017-11-01 | $494.00K derived: sum of 2 quarters · filed 2017-11-01 | $494.00K 10-Q · filed 2017-11-01 | $494.00K derived: sum of 4 quarters · filed 2018-04-30 |
| 2017-06-30 | $61.00K 10-Q · filed 2017-08-03 | $61.00K 10-Q · filed 2017-08-03 | $61.00K derived: sum of 3 quarters · filed 2018-04-30 | $61.00K derived: sum of 4 quarters · filed 2018-04-30 |
| 2017-03-31 | $0.00 10-Q · filed 2018-04-30 | $0.00 derived: sum of 2 quarters · filed 2018-04-30 | $0.00 derived: sum of 3 quarters · filed 2018-04-30 | $0.00 derived: sum of 4 quarters · filed 2018-04-30 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $0.00 derived: sum of 2 quarters · filed 2018-02-13 | $0.00 derived: sum of 3 quarters · filed 2018-02-13 | $0.00 10-K · filed 2018-02-13 |
| 2016-09-30 | $0.00 10-Q · filed 2017-11-01 | $0.00 derived: sum of 2 quarters · filed 2017-11-01 | $0.00 10-Q · filed 2017-11-01 | |
| 2016-06-30 | $0.00 10-Q · filed 2017-08-03 | $0.00 10-Q · filed 2017-08-03 | ||
| 2015-12-31 | $0.00 10-K · filed 2018-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |